Abstracts Titles – 21st Annual ENETS Conference

13 – 15 March 2024 | Vienna | Austria

A. BASIC SCIENCE – GENETICS, EPIGENETICS, MIRNAS, OMICS

(A01) **Axling, F. et al.** Metformin inhibits small intestinal neuroendocrine tumor proliferation in vivo

(A02) **Backman, S. et al.** Identifying potential tumor drivers through integration of gene expression and DNA copy number in SI-NET

(A03) **Backman, S. et al.** The evolutionary history of metastatic pancreatic neuroendocrine tumors reveals a therapy driven route to high-grade transformation

(A04) **Chen, L. et al.** Single-cell transcriptomic analysis of small intestinal neuroendocrine tumors revealed potential mechanisms of mesenteric fibrosis

(A05) **Chouchane, A. et al.** Transcriptomic analysis of PanNET tumor progression from microtumor to metastasis in MEN1 patients

(A06) **Davis, E. et al.** Enhancer heterogeneity of lung carcinoids reveals sensitivity to FGF signaling inhibition

(A07) **Debnath, O. et al.** Unanticipated heterogeneity in high-grade large-cell neuroendocrine carcinoma pinpoints cell sub-state specific therapeutic targets

(A08) **Frizziero, M. et al.** Cell-free DNA (cfDNA) methylation profiling for minimally invasive cancer detection in patients with Extra-Pulmonary NeuroEndocrine Carcinoma (EP-NEC)

(A09) **Ibáñez-Costa, A. et al.** Unravelling the RNA landscape of small intestine neuroendocrine neoplasms applying transcriptomic and spliceosomic perspectives

(A10) **Kaplinsky, A. et al.** Evaluating a possible association between promoter methylation level of genes encoding catecholamine metabolizing enzymes and metanephrine secretion in pheochromocytoma and paraganglioma

(A11) **La Salvia, A. et al.** Prognostic significance of metabolomics clusters in extra-pancreatic NETs: Lung NET sub-analysis

(A12) **Lin, X. et al.** Immune landscape of small intestinal neuroendocrine tumor at single-cell level

(A13) **Liu, S. et al.** Dissecting the intro- and inter-tumor heterogeneity of adrenocortical carcinoma by single-cell multi-omics analyses

(A14) **Liu, M. et al.** Dissecting the single-cell transcriptome network underlying thymic neuroendocrine tumor and thymus non-malignant tissues

(A15) **Mäkinen, N. et al.** Characterising the tumor microenvironment of multifocal small intestinal NETs

(A16) **Mariën, L. et al.** Detecting NET using Methylation-based biomarkers and the novel IMPRESS technology

(A17) **Mathian, E. et al.** Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumors in the lungNENomics project

(A18) **Moreno Montilla, M. et al.** Transcriptomic and spliceosomic landscapes of pancreatic neuroendocrine tumors generated through Oxford Nanopore Technology sequencing

(A19) **Nyirő, G. et al.** Differences in the microRNA expression of G1 and G2 pancreatic neuroendocrine tumors

(A20) **Pedraza-Arévalo, S. et al.** Specific spliceosomic landscapes reveal a possible link between RNA processing and panNETs behaviour

(A21) **Salimgereeva, D. et al.** Prevalence of germline mutations in pancreatic neuroendocrine tumors

(A22) **Simbolo, M. et al.** Integrative molecular analysis of lung neuroendocrine neoplasms with different Ki-67 indices identifies a molecular transition group between low- and high-grade neoplasms

(A23) **Song, Y. et al.** Inactivation of PHLDA3 gene leading to tumorigenesis of pancreatic neuroendocrine tumors and its molecular mechanisms

(A24) **Sun, Y. et al.** Germline mutation spectrum of neuroendocrine tumors

(A25) **Tan, H. et al.** Thoughts on the results of genetic map of a family

(A26) **Trevisani, E. et al.** DNA damage repair genes alterations in pancreatic neuroendocrine tumor treated with Temozolomide

(A27) **Webster, A. et al.** Epigenetic prediction of aging and metabolic traits provides insight into tumor biology in multi-focal ileal neuroendocrine tumors

(A28) **Wen, Y. et al.** Clinical and epidemiological profile of neuroendocrine differentiation – A hospital-based retrospective study

(A29) **Ye, M. et al.** m6A modifications promote the invasion and metastasis of pancreatic neuroendocrine neoplasms by activating the Integrin/FAK signalling pathway via TGFBI

(A30) **Ye, Z. et al.** Single-cell sequencing reveals the heterogeneity of pancreatic neuroendocrine tumors under the pattern of genomic instability and histological grading

B. BASIC SCIENCE – IN-VITRO MODELS, TUMOR GROWTH, CTCS

(B01) **Bräutigam, K. et al.** Decoding and targeting of metabolic heterogeneity in pancreatic neuroendocrine tumors (PanNETs): MCT1 and MCT4 in the crosshair for precision therapy

(B02) **Castanho Martins, M. et al.** Mesenteric fibrosis in small intestinal neuroendocrine tumors (SI-NETs): Pathogenesis and therapeutic targets

(B03) **Chaoul, N. et al.** Ex vivo expansion of TILs from panNET liver metastasis: In search of novel adoptive transfer strategies for the treatment of NETs

(B04) **Hu, S. et al.** Establishment of a rat model of diarrhea induced by Surufatinib

(B05) **Kulathunga, N. et al.** Establishment of novel patient-derived preclinical models for neuroendocrine tumors

Selected for Oral Abstract Presentation | **Selected for Oral Poster Presentation**

(B06) **Sela Peremen, L. et al.** Uncovering the role of netrins and DCC (deleted in colorectal cancer) in pancreatic neuroendocrine neoplasms (PNEN) tumorigenesis

(B07) **Tornesello, M. et al.** Anticancer activity of Cabozantinib and Temozolomide in cell lines derived from lung carcinoid and pancreatic neuroendocrine tumors

(B08) **Viol, F. et al.** Aurora kinase A inhibition as a promising therapeutic strategy in ARID1A-mutated neuroendocrine carcinomas: First results of an in vitro and in vivo study

(B09) **Wang, Y. et al.** Construction and comparison of non-functional pancreatic neuroendocrine tumor models

(B10) **Wang, F. et al.** Hepatic metastatic model establishment of pancreatic neuroendocrine tumor by hemi-splenectomy

(B11) **Ye, Z. et al.** The stromal microenvironment endows pancreatic neuroendocrine tumors with spatially specific invasive and metastatic phenotypes

(B12) **Zuo, X. et al.** Development of clinically representative patient-derived organoid models for diverse G1/G2 gastroenteropancreatic neuroendocrine tumors

C. BASIC SCIENCE – SIGNALLING PATHWAYS, RECEPTORS, BIOMARKERS

(C01) **Angelioudaki, I. et al.** Plasma extracellular vesicles number and size distinguish patients with neuroendocrine neoplasms

(C02) **Bolduan, F. et al.** Sortilin: A novel marker and potential therapeutic target for functional neuroendocrine tumors

(C03) **Calabrese, C. et al.** The role of adipocytes in neuroendocrine neoplasms: Molecular and metabolic adaptations

(C04) **García Vioque, V. et al.** The somatostatin system – A silent messenger in pheochromocytomas and paragangliomas?

(C05) **Gorai, P. et al.** Proteomic profiling reveals C1QA and COMP as promising plasma biomarkers for early detection of pancreatic neuroendocrine tumors

(C06) **Gu, D. et al.** Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K/AKT/mTOR pathway to promote the progression of pancreatic neuroendocrine neoplasms

(C07) **Hu, C. et al.** FOXA2-initiated transcriptional activation of INHBA induced by methylmalonic acid promotes pancreatic neuroendocrine neoplasm progression

(C08) **Ji, S. et al.** MEN1 deficiency-regulated MGMT expression controls Temozolomide tolerance of pancreatic neuroendocrine tumors

(C09) **Ji, S. et al.** Telomerase-independence function of Dyskerin is therapeutic vulnerability in TP53 mutant pancreatic neuroendocrine tumors

(C10) **Lens-Pardo, A. et al.** Validation of a 3-gene signature of response to axitinib in patients with advanced NETs

(C11) **Liu, S. et al.** Machine learning-based identification of disulfidptosis-associated signature for improving outcomes and immunotherapy responses in patients with adrenocortical carcinoma

(C12) **Liu, M. et al.** Network pharmacology reveal the mechanism of Cordycepin and neuroendocrine tumors

(C13) **Malavasi, E. et al.** PTK2 PROTAC unveiled as a selective inhibitor of gastrointestinal neuroendocrine cell proliferation via multi-target drug screening

(C14) **Zhang, W. et al.** Small extracellular vesicles miR-183-5p derived from highly invasive pancreatic neuroendocrine tumors reprogram macrophages towards SPP1+ macrophages

D. EPIDEMIOLOGY / NATURAL HISTORY / PROGNOSIS – REGISTRIES, NATIONWIDE AND REGIONAL SURVEYS

(D01) **Al-Toubah, T. et al.** Do metastatic appendiceal NETs ever develop metachronously after appendectomy or right hemicolectomy?

(D02) **Amin, T. et al.** CHGA and DAXX/ATRX expression influence the outcome of pancreatic head neuroendocrine tumors

(D03) **Apostolidis, L. et al.** Primary hepatic neuroendocrine neoplasms – Clinical characteristics and treatment outcomes of a rare disease

(D04) **Argente Pla, M. et al.** Just a matter of weight? Final results from NUTRIGETNE study in patients with Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)

(D05) **Barkmanova, J. et al.** 14 years of the Czech Neuroendocrine Tumors Registry

(D06) **Bel-Ange, A. et al.** BRCA gene mutations and NEN – Is it just random or a meaningful coincidence?

(D07) **Belabdi, D. et al.** The risk of venous thromboembolism in neuroendocrine neoplasms: A single-center experience

(D08) **Benevento, E. et al.** Clinical manifestation and aggressiveness of duodenopancreatic neuroendocrine tumors (DP-NET) in patients with MEN1 syndrome: A possible role of exon 2 mutations in menin gene

(D09) **Cai, W. et al.** Clinicopathological characteristics and survival of head and neck neuroendocrine carcinoma

(D10) **Cannavale, G. et al.** Neuroendocrine neoplasms in the young: The experience of a single-center study

(D11) **Casabella, A. et al.** Bone health in neuroendocrine neoplasms

(D12) **Cehic, G. et al.** Peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine neoplasms: A prospective multi-site study evaluating quality of life and objective response

(D13) **Chan, J. et al.** US real-world study of the burden of medication in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

(D14) **Chen, X. et al.** Prevalence of depressive and anxiety symptoms and disorders in neuroendocrine neoplasms: A systematic review and meta-analysis

(D15) **Ciobanu, O. A. et al.** MEN1 syndrome across four generations

(D16) **Clement, D. et al.** The effect of the Covid-19 pandemic on the body composition of patients with gastroenteropancreatic neuroendocrine tumors using a somatostatin analogue

(D17) **Clement, D. et al.** The global leadership into malnutrition criteria reveals a high percentage of malnutrition which negatively influences overall survival in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with somatostatin analogues

(D18) **Clift, A. et al.** Identifying patients with undiagnosed small intestinal neuroendocrine tumors using statistical and machine learning: Model development and validation study

(D19) **Dai, C. et al.** Overview of 609 cases of neuroendocrine neoplasms

(D20) **de Hosson, L. D. et al.** Infrastructure FOr Rare Cancer in the NEtherlands, towards a comprehensive platform for early detection and diagnosis of rare cancers (FORCE), and especially neuroendocrine neoplasms (NEN)

(D21) **Del Olmo-García, M. et al.** Impact of nutritional status in the quality of life (QoL) of patients with advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) in Spain: NUTRIGETNE Study

(D22) **El Asmar, M. et al.** Factors influencing emergency admissions in patients with neuroendocrine neoplasms (NEN) in England 2016-2017

(D23) **Erdmann, F. H. et al.** Prediction of recurrence for grade 1-2 small bowel neuroendocrine neoplasms after curative-intended resection

(D24) **Fisher, J. et al.** Long-term outcomes for medically managed carcinoid heart disease patients: A retrospective, longitudinal survey

(D25) **Gallo, C. et al.** Exploring the biological and clinical heterogeneity of grade 2 pancreatic neuroendocrine tumors: Insights into diagnosis, prognosis, and therapeutic targets

(D26) **González-Devia, D. et al.** Neuroendocrine tumors in pediatrics and young adults

(D27) **Han, D. et al.** Unveiling racial disparities in hepatic neuroendocrine tumors: A comprehensive analysis

(D28) **Hassan, D. et al.** Sexual dimorphism in small intestinal NETs: Any association with development of mesenteric metastases?

(D29) **Hernando, J. et al.** Incidence patterns and clinical implications of venous thromboembolism (VTE) in patients (pts) with neuroendocrine neoplasms (NEN)

(D30) **Huang, Z. et al.** Neuroendocrine differentiation in gastric cancer: Epidemiological insights and therapeutic implications

(D31) **Hunaut, T. et al.** Familial midgut neuroendocrine tumors (FM-NETs): Results of the nationwide TCF cohort from the GTE-RENATEN network

(D32) **Islam, O. et al.** Quali-NET: A prospective study on patient-reported quality of life in neuroendocrine neoplasms

(D33) **Jain, D. et al.** Pulmonary neuroendocrine tumors – Symptomatology, tumor characteristics, treatment strategies, and long-term outcomes in 37 Patients

(D34) **Karapanagioti, A. et al.** Long-term natural history of enterochromaffin-like cell (ECL) hyperplasia

(D35) **Konyakhina, A. et al.** Characteristics of gastric neuroendocrine tumors type 1

(D36) **Laffi, A. et al.** Grade 2 (G2) gastro-entero-pancreatic (GEP) neuroendocrine tumors (NETs): Risk stratification beyond Ki-67?

(D37) **Liccardi, A. et al.** Gender differences in lung neuroendocrine tumors: A single-center experience

(D38) **Lijun, Y. et al.** Clinical characteristics and prognostic factors analysis of 75 patients with neuroendocrine neoplasms (NENs) in XinJiang region

(D39) **Maas, C. et al.** Disease-specific mortality in a single-center cohort of 427 patients with carcinoid syndrome

(D40) **Maciejewski, A. et al.** Splenic metastases in the course of neuroendocrine tumors – Are they really that uncommon?

(D41) **Magno, S. et al.** Epidemiology and outcomes of NET in a Portuguese cancer center

(D42) **Maly, M. et al.** Neuroendocrine tumors in the stomach: An epidemiological analysis of Belgian Cancer Registry data

(D43) **Maratta, M. et al.** Pivotal role of the multidisciplinary tumor board on the management of neuroendocrine neoplasms – Impact of MTB decisions in an ENETS Center of Excellence

(D44) **Massironi, S. et al.** Assessing the frequency of type I gastric neuroendocrine neoplasms in autoimmune atrophic gastritis: A multi-center study in Italy

(D45) **Mortagy, M. et al.** Prediction of survival for patients with neuroendocrine neoplasms (NENs) using multivariable cox regression and survival nomograms: Data from National Cancer Registration and Analysis Service (NCRAS, UK) Database

(D46) **Mortagy, M. et al.** Sex differences in survival of neuroendocrine neoplasms (NENs): Comparative study of patients from National Cancer Registration and Analysis Service (NCRAS, UK) and Surveillance, Epidemiology, and End Results (SEER, US) databases

(D47) **Møller, S. et al.** Recurrence free survival and disease-specific survival in patients with pancreatic neuroendocrine neoplasms: A single-center retrospective study of 413 patients

(D48) **Panzuto, F. et al.** Itanet national prospective database: A comprehensive analysis of epidemiology and clinical presentation of GEP-NEN in Italy

(D49) **Papadopoulou-Marketou, N. et al.** Metastatic potential and associated mortality in a Greek cohort of 123 MEN1 patients

(D50) **Penugonda, M. et al.** Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): An international case series

(D51) **Roman-Gonzalez, A. et al.** Clinical, genetic and histopathological characterisation of patients with multiple endocrine neoplasia type 1 in two high complexity hospitals in Medellín, Colombia

(D52) **Rossi, R. et al.** Gender role in the authorship of Italian academic medical literature on neuroendocrine neoplasms: Cliché or reality?

(D53) **Sabella, G. et al.** YAP-1 as prognostic marker for immunochemotherapy response in SCLC patients

(D54) **Slott, C. et al.** Outlook for 615 small intestinal neuroendocrine tumor patients: Recurrence risk after surgery and disease-specific survival in advanced disease

(D55) **Smiroldo, V. et al.** Preliminary experience with a new institutional dedicated neuroendocrine team in a tertiary

(D56) **Starr, J. et al.** Burden of medication in patients with lung neuroendocrine tumors (NETs) in a US real-world setting

(D57) **Sun, W. et al.** Malignancy of gastric neuroendocrine tumors is higher than pancreatic neuroendocrine tumors in Chinese population – Characterisation and analysis of factors

(D58) **Tang, L. et al.** High expression of ADAM15 in non-functional pancreatic neuroendocrine tumors is associated with high-density tumor-infiltrating neutrophils and predicts poor outcome

(D59) **Thuringer, J. et al.** Pelvic metastases in patients with neuroendocrine tumors: A rare site of metastases

Selected for Oral Abstract Presentation | **Selected for Oral Poster Presentation**

(D60) **Wedin, M. et al.** Clinical impact and prognosis of patients with Si-NET and bone metastases – Do they matter?
(D61) **Xue, B. et al.** Correlation between clinicopathologic features and prognosis of 196 cases of pancreatic neuroendocrine tumors
(D62) **Zea Lopera, J. et al.** National registry of pheochromocytomas and paragangliomas in the Colombian territory: Epidemiological insights and clinical profiles
(D63) **Zidane, H. et al.** Digestive neuroendocrine tumors in the Mostaganémoise region (western Algeria)

E. PATHOLOGY – GRADING, STAGING

(E01) **Ahn, B. et al.** Radiologic tumor border status can further stratify patients with pancreatic neuroendocrine tumor
(E02) **Al-Toubah, T. et al.** Association of long-term PPI use with low-risk gastric neuroendocrine tumor
(E03) **Andreasi, V. et al.** Prognostic significance of nodal micrometastases in patients with non-functioning pancreatic neuroendocrine tumors (NF-PanNETs) – A survival analysis from a prospective observational study
(E04) **Guedj, N. et al.** Clinical application of digital pathology: Proposal of a new G0 category useful in small intestinal NET (SI-NET)
(E05) **Guo, Y. et al.** Machine-learning identified optimised classification models for the diagnosis of typical and atypical lung carcinoids based on the genomic variance
(E06) **Gutierrez Gordo, M. et al.** The importance of pathological sample review in the initial workup study in reference centers: The experience of an ENETS Center of Excellence
(E07) **Huang, D. et al.** A combined nomogram to predict liver metastasis of pancreatic neuroendocrine tumors: Integrating deep learning radiomics and computational pathology
(E08) **Jiajing, L. et al.** Mixed neuroendocrine and non-neuroendocrine tumors of the digestive system (MiNEN): A clinicopathological observation
(E09) **Kasajima, A. et al.** New insights into the progression of NET G3 with a focus of NETs with NEC-like transformation
(E10) **Leunissen, D. et al.** Immunohistochemical profiling of lung carcinoid subtypes and marker comparison of matched primary and metastatic tumors
(E11) **Moser, E. et al.** Hormonally characterised NF-PanNETs and their clinicopathological features
(E12) **Sabella, G. et al.** Ordinary colorectal cancers expressing synaptophysin: Myth or reality?
(E13) **Xie, Z. et al.** Compare the optimal TNM staging of resectable functional and non-functional pancreatic neuroendocrine tumors

F. BIOMARKERS – CLINICAL APPLICATIONS

(F01) **Arenillas, C. et al.** Uncovering the genomic profiling of metastatic pheochromocytomas and paragangliomas: Leveraging plasma circulating tumor DNA for comprehensive genetic characterisation and monitoring
(F02) **Bourdeleau-Guerry, P. et al.** Temporal increase in Ki-67 index in patients with pancreatic neuroendocrine tumors (PanNETs): Frequency, prognostic impact, and causal factors
(F03) **Catoya, J. et al.** MAPK and mTOR pathway activation is associated with chemotherapy resistance and a poor prognosis in G3 advanced NENs
(F04) **Farinea, G. et al.** Precision medicine in advanced NENs: Molecular profiling and target actionability real world data
(F05) **Gagliardi, I. et al.** Comparative targeted NGS analysis between solid and liquid biopsies in GEP-NET: A pilot study
(F06) **Gagliardi, I. et al.** Liquid biopsy as a new tool for the molecular profiling of neuroendocrine neoplasms: The Gustave Roussy experience
(F07) **Jannin, A. et al.** Metabolite biomarker discovery for pancreatic neuroendocrine tumors using metabolomic approach
(F08) **Johansen, S. et al.** Tryptophan pathway metabolites as prognostic biomarkers of recurrent disease in curatively operated neuroendocrine tumor patients
(F09) **Jumai, N. et al.** Identification of gastroenteropancreatic neuroendocrine tumor with high liver tumor burden based on clinicopathological features
(F10) **Kerolles, M. et al.** Serum 5-hydroxyindoleacetic acid is equivalent to 24-hour urinary 5-hydroxyindoleacetic acid for the diagnosis of carcinoid syndrome
(F11) **Komarnicki, P. et al.** Serum b-HCG as a biomarker in neuroendocrine tumors: A reconsideration of single-analyte approach
(F12) **Lau, T. et al.** The role of fibrosis markers in predicting decline in renal function in patients undergoing PRRT
(F13) **Lecoeur, A. et al.** Interest of serum and urinary 5HIAA, serotonin, chromogranin A and NT-proBNP assays as predictive factors for the development of carcinoid heart disease in neuroendocrine tumors
(F14) **Mancini, C. et al.** Evaluation of the impact of indoleamine 2,3-deoxygenase (IDO) enzyme activity in neuroendocrine tumors (NETs)
(F15) **Minotta, R. et al.** Evaluation of Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR) and Systemic Immune-Inflammation Index (SII) as potential biomarkers in patients with sporadic pancreatic neuroendocrine tumors (pNET)
(F16) **Mulders, M. et al.** What is the carcinoid syndrome? A critical appraisal of its proposed mediators
(F17) **Pachnikova, G. et al.** Characterisation of new biomarkers from patients with neuroendocrine cancer using liquid biopsy methods
(F18) **Paravani, P. et al.** Prospective analysis of the risk of post-surgical recurrence in lung typical carcinoid
(F19) **Pokossy Epee, J. et al.** Prognostic impact of molecular signatures in pancreatic metastatic neuroendocrine tumors (PRODETEN)
(F20) **Raia, S. et al.** Immunohistochemical analysis for galectin-3 and outcomes in medullary thyroid cancer
(F21) **Salimgereeva, D. et al.** Role of gastric mucosa evaluation in diagnostic of pancreatic neuroendocrine tumors functional status
(F22) **Spada, F. et al.** A single institution experience of clinic-molecular characterisation and correlation with treatment outcomes in patients with advanced extrapulmonary high grade neuroendocrine carcinomas: The NIRVANA study
(F23) **Sponheim, J. et al.** 5-Hydroxymethylcytosine profiling of plasma-derived circulating free DNA in patients with pancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE

Selected for Oral Abstract Presentation | **Selected for Oral Poster Presentation**

(F24) **van Weert, T. et al.** Performance of a prognostic OTP, CD44, Ki-67 biomarker panel on paired biopsies and resections of lung carcinoids

(F25) **Verrico, M. et al.** New insight in the environment immunephenotyping of gastroenteropancreatic neuroendocrine neoplasms: CD 90 expression

(F26) **Yanling, X. et al.** Identification of new biomarkers associated with prognosis of pancreatic neuroendocrine neoplasms and establishment of survival prediction model

(F27) **Yin, L. et al.** Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine carcinomas and its potential diagnostic value

G. IMAGING AND INTERVENTIONS (RADIOLOGY, ENDOSCOPY, EMBOLISATION)

(G01) **Ahmed, Q. et al.** Artisan: Prospective phase II trial of TheraSphere Selective Internal Radiation Therapy (SIRT) for liver metastases in neuroendocrine tumors (NETs)

(G02) **Briol, D. et al.** Selective internal radiation therapy for neuroendocrine liver metastases: Efficacy, safety and prognostic factors – A retrospective single institution study

(G03) **Chen, J. et al.** Adverse events after endoscopic ultrasound-guided fine-needle aspiration and fine-needle biopsy in pancreatic neuroendocrine tumors: A systematic review

(G04) **Chen, L. et al.** Trans arterial embolisation for liver metastasis in patients with well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors

(G05) **Diamantopoulos, L. et al.** Patterns of radiotracer uptake in patients with resectable lung carcinoids undergoing preoperative functional imaging

(G06) **Feola, T. et al.** The diagnostic role of DWI-MRI for liver metastases of neuroendocrine neoplasms (NENs) in comparison with the functional imaging

(G07) **Gould, H. et al.** Hospital record data on the clinical presentation and diagnostic investigations of small intestinal neuroendocrine tumors (SI-NETs)

(G08) **Hijioka, S. et al.** Treatment strategy for pancreatic NETs smaller than 2 cm should be based on the diagnosis of malignancy as well – New treatment strategy for small pancreatic NETs

(G09) **Masoni, B. et al.** A single-center experience of locoregional treatments application in neuroendocrine liver metastases

(G10) **Nunez Rodriguez, J. et al.** Tolerability and outcomes of neuroendocrine tumors treated with peptide receptor radionuclide therapy and stereotactic body radiation therapy

(G11) **Ren, S. et al.** Prognostic role and predictors of lymph node involvement in pancreatic neuroendocrine tumors

(G12) **Rossi, R. et al.** Incidental endoscopic removal of a rectal neuroendocrine tumor: What to do?

(G13) **Roy, M. et al.** Diagnostic work-up for neuroendocrine tumors of occult primary at diagnosis: A retrospective monocentric study of 61 cases

(G14) **Shen, X. et al.** A nomogram to preoperatively predict the aggressiveness of non-functional pancreatic neuroendocrine tumors based on CT features

(G15) **Shen, X. et al.** Association of body composition with survival in patients with Pancreatic Neuroendocrine Tumors (PNET) following curative resection

(G16) **Tang, W. et al.** A CT-based radiomics and deep learning signature for evaluating the somatostatin receptor 2 in non-functional pancreatic neuroendocrine tumors: A multicohort, retrospective study

(G17) **Tang, W. et al.** Development and validation of CT-based radiomics deep learning signatures to preoperatively predict lymph node metastasis in non-functional pancreatic neuroendocrine tumor: A multi-cohort study

(G18) **Varghese, D. et al.** Machine learning model: Predicting prognosis in neuroendocrine tumors

(G19) **Vedie, A. et al.** Comparison of trans arterial embolisation (TAE) or chemoembolisation (TACE) using streptozotocin (STZ) and biomarker study in patients with metastatic neuroendocrine tumors (NET)

(G20) **von Stempel, C. et al.** Validation of a radiomics model to predict symptoms complications from small intestinal NET mesenteric metastases – Preliminary report

(G21) **Yu, H. et al.** The efficacy and safety analysis of trans arterial embolisation in the treatment of cystic neuroendocrine neoplasm liver metastasis

H. NUCLEAR MEDICINE – IMAGING AND THERAPY (PRRT)

(H01) **Barone, A. et al.** Neoadjuvant PRRT with 90Y-DOTATOC: Preliminary results from a monocentric perspective study

(H02) **Bian, L. et al.** Comparison of the diagnostic value of 68Ga-DOTANOC, 18F-FDOPA, and18F-FDG PET/CT for metastatic paraganglioma

(H03) **Bian, J. et al.** The application of 68Ga-DOTANOC PET/CT after endoscopic submucosal dissection for patients with rectal NET

(H04) **Boehm, E. et al.** Peptide Receptor Radionuclide Therapy (PRRT) in the management of patients with ectopic Cushing's syndrome due to metastatic gastroenteropancreatic neuroendocrine neoplasia (GEPNEN): A single-center experience

(H05) **Chan, D. et al.** Metabolic tumor volume (MTV) as a biomarker in patients with gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): A multi-center study

(H06) **de Herder, W. et al.** [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomised NETTER-2 study

(H07) **Georgakopoulos, A. et al.** Delays in the dosing administration of PRRT in advanced neuroendocrine tumors – Is there an adverse impact?

(H08) **Leupe, H. et al.** PET/CT imaging of the somatostatin receptor with [18F]AlF-NOTA-octreotide PET/CT: Analysis of impact on tumor staging and therapeutic management

(H09) **Lopes-Pinto, M. et al.** Functioning neuroendocrine neoplasms: Symptomatic control with 177Lu-DOTATATE

Selected for Oral Abstract Presentation | Selected for Oral Poster Presentation

(H10) **Maas, C. et al.** Peptide receptor radionuclide therapy is effective for hormonal control of carcinoid syndrome

(H11) **Martinez Lago, N. et al.** Real-world efficacy and safety of re-treatment with [177Lu] Lu-DOTA-TATE in patients with neuroendocrine tumors (NETs)

(H12) **Mileva, M. et al.** Grade ≥3 subacute haematological toxicity with 177Lu-DOTATATE PRRT – Results from LUMEN study

(H13) **Negre, M. et al.** Lutetium-177 Dotatate Peptide Receptor Radionuclide Therapy in metastatic pheochromocytoma and paraganglioma: Experience in our center

(H14) **Okamoto, K. et al.** Safety and efficacy of peptide radionuclide therapy (PRRT) with 177Lu-DOTATATE for Japanese patients with neuroendocrine neoplasm (NEN): A single-center retrospective study

(H15) **Opalinska, M. et al.** TECANT ERA PerMed study – Somatostatin receptor antagonists as a new sensitive diagnostic tool for reliable assessment of the SSTR status in neuroendocrine neoplasms

(H16) **Oziel-Taieb, S. et al.** Predictive factors of persistent thrombocytopenia after 177Lu-DOTATATE in patients with neuroendocrine tumors

(H17) **Pelle, E. et al.** Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lutetium-DOTATATE

(H18) **Sánchez Gómez, L. et al.** 177Lu-DOTATATE (177Lu) efficacy in metastatic well-differentiated neuroendocrine tumors (wdNET): Differences in response according to metastases (met) location

(H19) **Sansovini, M. et al.** 177Lu-dotatate as salvage therapy in bronchial and GEP NET patients: The IRST "Dino Amadori" experience

(H20) **Singh, A. et al.** Routine early 68Ga-DOTATATE PET/CT has low diagnostic yield after resection of pancreatic neuroendocrine neoplasms

(H21) **Sponheim, J. et al.** Peptide receptor radionuclide treatment in an outpatient setting – A single-center experience

(H22) **Stolniceanu, C. et al.** The quantitative assessment importance in NETs diagnosis

(H23) **Strosberg, J. et al.** Phase Ib portion of the ACTION-1 Phase Ib/3 trial of RYZ101 in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) progressing after 177Lu somatostatin analogue (SSA) therapy: Safety and efficacy findings

(H24) **Warfvinge, C. et al.** Relationship between absorbed dose and response in neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE

(H25) **Weich, A. et al.** Prostate-specific membrane antigen-targeting theranostics in neuroendocrine neoplasms – Initial results from the GI-PSMA phase II trial

(H26) **Xu, J. et al.** The value of 68Ga-DOTANOC and 18F-FDG PET/CT for predicting the prognosis of patients with metastatic rectal neuroendocrine tumor

(H27) **Yi, Z. et al.** Heterogenous uptake of 68Ga-DOTATATE and 18F-FDG in patients with initially diagnosed neuroendocrine tumors: Which patients are suitable for dual-tracer PET imaging?

I. MEDICAL TREATMENT – ALL TYPES OF SYSTEMIC ANTI-CANCER THERAPIES (SACT)

(I01) **Bechairia, W. et al.** Digestive neuroendocrine tumors diagnosis and therapeutic particularities: Experience of medical oncology center of Annaba, Algeria

(I02) **Benguedddach, A. et al.** 8-year follow-up reveals therapeutic approaches for patients with neuroendocrine neoplasms – Findings from the TNE West Network: 2016-2023

(I03) **Capdevila, J. et al.** Updated data from a phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumors: Focus on extrapulmonary neuroendocrine carcinomas (epNECs)

(I04) **Chai, M. et al.** Promising outcomes with surufatinib-vinorelbine combination therapy in lung cancer with neuroendocrine differentiation

(I05) **Cheng, Z. et al.** Treatments, clinicopathological characteristics and prognosis in thymic neuroendocrine tumors (TNETs): With especial reference to Temozolomide (TMZ)-based chemotherapy

(I06) **Chi, Y. et al.** S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumors (STEM): A randomised, open-label, multi-center phase 2 trial

(I07) **Clement, D. et al.** High prevalence of deficiencies in fat-soluble vitamins, minerals and trace elements but no relation with malnutrition in patients with gastroenteropancreatic neuroendocrine tumors using somatostatin analogues

(I08) **Dasari, A. et al.** A phase II study of Lenvatinib and Everolimus in advanced well-differentiated extra pancreatic neuroendocrine tumors

(I09) **de Mestier, L. et al.** Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well-differentiated pancreatic neuroendocrine tumors

(I10) **Duan, X. et al.** Molecular typing and mutational characterisation of rectal neuroendocrine neoplasms

(I11) **Evdokimova, E. et al.** Analysis of the NET G3 of lungs

(I12) **García-Álvarez, A. et al.** Durvalumab (D) plus Tremelimumab (T) for the treatment of patients with progressive, advanced medullary thyroid carcinoma (MTC) – DUTHY (GETNE-T1812) trial

(I13) **Gervaso, L. et al.** Risk of venous thromboembolism according to molecular profiling in patients with neuroendocrine carcinoma

(I14) **Islam, O. et al.** Sequential Everolimus and Sunitinib treatment in progressive, advanced, pancreatic NENs: Real-world data from the Belgian Group of Digestive Oncology DNET & NETwerk

(I15) **Jiang, L. et al.** The safety and efficacy of surufatinib for the treatment of advanced neuroendocrine tumors: A prospective, multi-center, real-world study

(I16) **Konyakhina, A. et al.** Gastric mucosa conditions during atrophic gastritis and gastric neuroendocrine neoplasia type 1 (gNEN 1)

(I17) **Li, X. et al.** Camrelizumab plus chemotherapy as first-line treatment for advanced extrapulmonary neuroendocrine carcinoma: An investigator-initiated phase 2 study (CAMEC trial)

(I18) **Li, X. et al.** Comparative efficacy of Surufatinib plus transarterial embolisation versus Surufatinib monotherapy in neuroendocrine tumor with liver metastasis: A prospective, randomised, controlled trial

(I19) **Liu, M. et al.** Efficacy, safety and prognostic factors of Capecitabine plus Temozolomide regimen in patients with thymic neuroendocrine neoplasms

(I20) **Maratta, M. et al.** Upfront Oxaliplatin–Fluoropyrimidine chemotherapy and Somatostatin Analogues (SSA) in advanced well-differentiated G2/G3 gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs)

(I21) **Molina-Cerrillo, J. et al.** Responses to Cabozantinib plus Atezolizumab in a wide population of advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II Trial (CABATEN / GETNE-T1914)

(I22) **Ramos, M. et al.** Real world data of CAPTEM in metastatic neuroendocrine tumors

(I23) **Romano, E. et al.** Prevalence of sarcopenia in patients with advanced intestinal neuroendocrine neoplasms at time of diagnosis

(I24) **Sorbye, H. et al.** Nordic NEC 2: Characteristics and treatment outcome in a prospective cohort of 698 patients with high-grade digestive neuroendocrine neoplasms (NET G3 and NEC)

(I25) **Spada, F. et al.** An Italian multi-center phase II trial of Metronomic Temozolomide in unfit patients with advanced neuroendocrine neoplasms: MeTe study

(I26) **Srirajaskanthan, R. et al.** Development of a mobile app for patients with neuroendocrine neoplasms: A collaborative project between United Kingdom NET Society and Neuroendocrine Tumour Patient Foundation

(I27) **Su, T. et al.** Effectiveness and safety of surufatinib in treating pheochromocytomas and paragangliomas

(I28) **Thuringer, J. et al.** Octreotide infusion pump in patients with functional neuroendocrine tumors and refractory hormonal syndromes

(I29) **Usiskin, K. et al.** Interim safety and exploratory efficacy results of a phase 2, randomised, parallel-group study of oral Paltusotine treatment in subjects with carcinoid syndrome

(I30) **Wang, Z. et al.** A prospective, open-label study evaluating the efficacy and safety of Surufatinib (S) in combination with CAPTEM as conversion therapy in patients with unresectable pancreatic neuroendocrine tumors (pNET)

(I31) **Wang, W. et al.** Efficacy and safety of Surufatinib in combination with CAPTEM for patients with advanced G2/G3 NETs: Preliminary results from a single-arm, phase II study

(I32) **Wang, Y. et al.** Real-world study of Surufatinib combined with hepatic artery infusion chemotherapy (HAIC) for high-grade neuroendocrine neoplasm

(I33) **Wotherspoon, I. et al.** A review of the Scottish national Peptide Receptor Radionuclide Therapy (PRRT) service with focus on patients with small bowel neuroendocrine tumors (SBNET) treated between April 2019 and March 2021

(I34) **Zhang, L. et al.** Brachytherapy in craniopharyngiomas: A systematic review and meta-analysis of long-term follow-up

(I35) **Zhang, P. et al.** Surufatinib plus Sintilimab and IBI310 in patients with high-grade advanced-neuroendocrine neoplasm (HG-NEN): A multi-center, single arm phase 2 study

(I36) **Zhulikov, Y. et al.** Efficiency of GemCap + mitotane in platinum and mitotane resistant adrenocortical carcinoma

(I37) **Zhulikov, Y. et al.** Temozolomide as second and subsequent lines of treatment in metastatic adrenocortical cancer: Prospective phase II clinical trial

J. SURGICAL TOPICS

(J01) **Barnard, P. et al.** Management and surveillance for rectal neuroendocrine tumors: A single-center retrospective analysis and comparison with ENETS guidelines

(J02) **Battistella, A. et al.** Factors associated with post-operative pancreatic insufficiency after distal pancreatectomy for localised non-functioning pancreatic neuroendocrine tumors (NF-PanNET)

(J03) **Bennaoum, S. M. E. A. et al.** Digestive neuroendocrine tumors – Retrospective study and experience of the general surgery department of EHU Oran

(J04) **Bennaoum, S. M. E. A. et al.** Pancreatic neuroendocrine tumors – Epidemiological profile and surgical aspects

(J05) **Bertani, E. et al.** Radio-guided surgery with a new generation β-probe for radiolabelled somatostatin analogue, in patients with small intestinal neuroendocrine tumors – A Phase II surgical trial

(J06) **Borbon, L. et al.** Peptide Receptor Radionuclide Therapy improves progression free and overall survival in patients who progress after resection of gastroenteropancreatic NETs

(J07) **Chibane, A. et al.** Surgery of small bowel neuroendocrine tumors: 10 years' experience at a tertiary center

(J08) **Clift, A. et al.** 10 years' experience of managing small intestinal neuroendocrine tumors at an ENETS Center of Excellence

(J09) **Gajda, M. et al.** Risk factors of clinically relevant pancreatic fistula after pancreaticoduodenectomy for pancreatic neuroendocrine tumors – Single-center retrospective study

(J10) **Kalepu, J. et al.** Leak rates in pancreatico-duodenectomy procedures in pancreatic NETs compared to pancreatic ductal adenocarcinoma resections

(J11) **Liang, Y. et al.** Liver debulking surgery affect the treatment efficacy of SSAs

(J12) **Manoharan, J. et al.** Evaluation of circulating extracellular vesicles as suitable prognostic markers in MEN1-associated non-functioning pancreatic neuroendocrine neoplasia

(J13) **Nießen, A. et al.** Portal vein resection in pancreatic neuroendocrine neoplasms

(J14) **Palaniappan, V. et al.** A systematic review of hepatic transplantation for neuroendocrine liver metastases – Focus on long-term outcomes

(J15) **Pasquali, C. et al.** Pancreatic neuroendocrine tumors mimicking pancreatic metastases from renal neoplasms

(J16) **Pencréac'h, S. et al.** The contribution of functional imaging in predicting the risk of recurrence after pancreatic surgery for neuroendocrine tumors

(J17) **Sponheim, J. et al.** Valvular surgery in carcinoid heart disease – Indications and outcome

(J18) **Wang, F. et al.** Mapping of lymph node metastasis in non-functional pancreatic neuroendocrine tumors: A retrospective analysis of 455 patients

Selected for Oral Abstract Presentation | **Selected for Oral Poster Presentation**

K. OTHER RARE NENS TO INCLUDE NON-DIGESTIVE AND NON-THORACIC E.G. PHAEOS / PGL AND MTC

(K01) **Dai, C. et al.** Clinical and pathological characteristics of 77 cases of extra adrenal paraganglioma
(K02) **Di Iasi, G. et al.** Pheochromocytoma and paraganglioma: Gender differences in lipid profile
(K03) **Halperin, R. et al.** Uncommon manifestations in type 4 familial paraganglioma syndrome – A large cohort of patients harbouring the SDHB p.Q214Ter variant
(K04) **Tan, H. et al.** Analysis of the efficacy of STEM chemotherapy in patients with metastatic paraganglioma

L. CASE REPORTS

(L01) **Azarraga, C. et al.** Intra-arterial Peptide Receptor Radionuclide Therapy in a Filipino male with predominantly hepatic metastasis in a known primary pancreatic neuroendocrine tumor
(L02) **Bennaoum, S. M. E. A. et al.** Breast neuroendocrine carcinomas surgery: A case report
(L03) **Blanco Cuso, L. et al.** Cystic Pancreatic Neuroendocrine Tumors: Rare but more common?
(L04) **Cai, W. et al.** Mediastinal neuroendocrine tumor with heart metastasis response to immunotherapy
(L05) **Chianpian, C. et al.** Complete and sustained response after peptide receptor radionuclide therapy in a 66-year-old Filipino male with metastatic pancreatic neuroendocrine tumor: A case report primary
(L06) **Cidade Rodrigues, C. et al.** Non-functional alpha-cell hyperplasia with glucagonoma: A case report
(L07) **Falkman, L. et al.** BRAF/MEK combination treatment in a patient with BRAF mutated neuroendocrine carcinoma
(L08) **Florez, A. et al.** Idiopathic diffuse neuroendocrine diffuse neuroendocrine hyperplasia - A case report
(L09) **González Devia, D. et al.** 68-Gallium DOTANOC PET/CT pitfall in adnexal tumor
(L10) **Jia, X. et al.** A case report of a high-grade pancreatic NET patient with high tumor mutation burden who benefited from chemotherapy combined with immunotherapy
(L11) **Jimenez Gordo, A. et al.** Synchronous case of advanced gastric Her-2 + adenocarcinoma and metastatic neuroendocrine neoplasm of unknown origin – A MiNEN case?
(L12) **Kaid, M. et al.** Carcinoid heart in neuroendcrine tumor – Experience of medical departement oncology Oran, Algeria
(L13) **Kontana, E. et al.** Olaparib use in a patient diagnosed with BRCA2 mutated adrenocortical carcinoma: A case report
(L14) **Liang, Y. et al.** SDHx germline mutation in thymic neuroendocrine tumors
(L15) **Liang, Y. et al.** Testicular neuroendocrine tumors – A retrospective study (five cases)
(L16) **Mathara Diddhenipothage, S. et al.** Metastatic insulinoma – A clinical conundrum
(L17) **Mulders, M. et al.** Ovarian neuroendocrine tumor metastases can induce estrogen production in postmenopausal patients
(L18) **Na, H. et al.** Clinical value of endoscopic submucosal dissection combined with chemotherapy for treatment of oesophageal neuroendocrine carcinoma
(L19) **Peiró, I. et al.** Hypercalcemia due to parathyroid hormone-related protein (PTHrP) secretion in pNETs: A series of cases
(L20) **Rehman, Z. et al.** Liver transplantation for neuroendocrine tumor liver metastases: UK and Ireland's pioneering pilot programme
(L21) **Roman-Gonzalez, A. et al.** 18 F-DOPA PET/CT leading to diagnosis of micro pheochromocytoma
(L22) **Samia, K. et al.** Primary hepatic neuroendocrine tumor in a series of 8 cases
(L23) **Sherriff, D. et al.** Immediate and sustained response of hypoglycaemia to Streptozotocin-based chemotherapy in metastatic Insulinoma: A case report
(L24) **Sherriff, D. et al.** Management of unresectable insulinoma using cloud-based continuous glucose monitoring: A case report
(L25) **Sun, Y. et al.** ALK-targeted therapy in atypical carcinoid of the lung: A case report
(L26) **Tan, H. et al.** A case of multiple endocrine neoplasia type 1 (MEN1) phenotype caused by CDC73 mutation
(L27) **Tan, H. et al.** A case report of metastatic mediastinal MiNEN with clinical complete remission
(L28) **Tőke, J. et al.** Tricuspid valve replacement and liver transplantation in a 51-year-old female patient with grade 1 ileum NET and refractory carcinoid syndrome
(L29) **Torresan, I. et al.** Pit and pitfalls of tumor mutational burden assessment in well-differentiated pancreatic neuroendocrine tumors: Two case reports from University of Verona
(L30) **Tu, R. et al.** Carcinoid syndrome caused by pulmonary neuroendocrine tumor liver metastases: A case report
(L31) **Verdasca, F. et al.** Mixed neuroendocrine-non-neuroendocrine neoplasms of the rectum: A case report
(L32) **Xie, Z. et al.** A case of conversion therapy for pancreatic neuroendocrine tumor with liver metastasis using Surufatinib combined with CAPTEM
(L33) **Xu, X. et al.** Heterogeneity of multiple pancreatic neuroendocrine tumors identified by 68Ga-DOTANOC and 68Ga-exendin-4 PET/CT in a patient with endogenous hyperinsulinemic hypoglycaemia and multiple endocrine neoplasia 1
(L34) **Yanping, Z. et al.** A case of functional pancreatic neuroendocrine tumor with hypercalcemia as the main manifestation
(L35) **Yu, F. et al.** Type 1 gastric neuroendocrine tumors (g-NETs) with vitamin B12 deficiency-caused nerve function damage – A case Report

M. TRIALS-IN-PROGRESS / TRIAL CONCEPTS

(M01) **Asp, P. et al.** START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors – An open-label, multi-center, randomised phase III trial comparing safety and efficacy of personalised vs non-personalised radionuclide therapy with 177Lu-DOTATOC

Selected for Oral Abstract Presentation | **Selected for Oral Poster Presentation**

(M02) **Capdevila, J. et al.** DAREON™-7: A Phase I, open-label, dose escalation and expansion cohort trial of the delta-like ligand (DLL3)-targeting T-cell engager BI 764532, plus first-line platinum-based chemotherapy in patients with DLL3-positive neuroendocrine carcinomas

(M03) **Chan, D. et al.** CAPTEM and PRRT to improve overall response for pancreatic NETs (pNETs) – The CORONET trial

(M04) **Chhajlani, S. et al.** Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumor pAtients (SAUNA trial) – Study protocol for a bi-national, multi-center, open-label, randomised, pragmatic clinical trial

(M05) **García-Álvarez, A. et al.** A phase 3 randomised study of 177Lu-edotreotide or everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (LEVEL, GETNE-T2217)

(M06) **Martinez Lago, N. et al.** Empowering patients with neuroendocrine tumors through a mobile app: NETcare

(M07) **Opalinska, M. et al.** Personalised dosimetry as a key for optimising radioligand therapy (RLT) with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE in patients with neuroendocrine tumors – The DUONEN multi-center study

(M08) **Ralic, D. et al.** Analysis of AI-based clinical trial search tool usage reveals motivations of neuroendocrine tumors patients in searching for trials

(M09) **Rzeniewicz, K. et al.** Interim analysis of LANTana: Phase Ib study investigating up-regulation of somatostatin receptor-2 (SSTR2) with the de-methylating agent ASTX727 to allow [177Lu]Lu-DOTA-TATE in metastatic neuroendocrine tumors (NETs)

(M10) **Singh, S. et al.** ACTION-1: A randomised phase Ib/3 trial of RYZ101 compared with standard of care in somatostatin receptor positive, well-differentiated gastroenteropancreatic neuroendocrine tumors with progression following 177Lu somatostatin analogue therapy

(M11) **Singh, S. et al.** Status of the ongoing SORENTO clinical trial: Assessing efficacy and safety of high-exposure octreotide subcutaneous depot in patients with GEP-NET

(M12) **Srirajaskanthan, R. et al.** Genomic profiling in the randomised controlled phase III COMPOSE trial of Lu-177 edotreotide for well-differentiated aggressive grade 2/3 gastroenteropancreatic-neuroendocrine tumors

N. NURSING AND ALLIED TOPICS - NURSING

(N01) **Jervis, N. et al.** Co-production of patient information: A model for today's practice

(N02) **Wakelin, K. et al.** Implementation of a new, nurse-led clinic (NLC) for neuroendocrine tumor (NET) patients

O. NURSING AND ALLIED TOPICS – DIETETICS

P. NURSING AND ALLIED TOPICS – PSYCHO-SOCIAL TOPICS

(P01) **Jervis, N. et al.** Evaluation of the utility of group therapy as a mechanism of delivering facilitated psychosocial support to those with a neuroendocrine neoplasm diagnosis

(P02) **Luijendijk, M. et al.** Psychiatric and cognitive function in patients with serotonin producing neuroendocrine tumors